Marcelo Falchi
Psychiatrist, Professor of Medicine at the Federal University of Rio Grande do Norte (UFRN), and Medical Director at the Center for Advanced Psychedelic Medicine (CAMP)
Data updated
Research Footprint
Marcelo Falchi appears in 6 tracked papers (2021–2024), most studied alongside LSD, Psilocybin and DMT, across Healthy Volunteers, Anxiety Disorders and Substance Use Disorders (SUD).
Most-cited paper: LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model (52 citations).
Frequent co-authors: Fernanda Palhano-Fontes, Lukas Wießner and Isabel Wießner.
Background & Research
Marcelo Falchi is a Brazilian psychiatrist and physician-scientist focused on psychedelic science, neuropsychiatry, and novel treatments for depression. He is described as a master’s-level psychiatrist trained at UNICAMP, a professor in UFRN’s medical program, and Medical Director of CAMP; he has also led psychiatric research at Biomind Labs and worked on first-in-world or first-in-Brazil psychedelic clinical studies.
Key Impact
He is a Brazilian psychiatrist and psychedelic-science researcher involved in pioneering LSD and DMT clinical studies, including work on cognition, creativity, language, and inhaled DMT safety.
Collaboration Network
17 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Marcelo Falchi is associated with.
Federal University of Rio Grande do Norte (UFRN)
Federal University of Rio Grande do Norte is a public research university in Brazil with active neuroscience and mental health research programmes, including work linked to psychedelic science through affiliated institutes.
View stakeholder →Biomind Labs
Public BiotechBiomind Labs (NEO: BMND) is a Canadian clinical-stage biopharmaceutical company developing inhaled DMT, sublingual 5-MeO-DMT, and mescaline-class compounds across TRD, Alzheimer's-related depression, obesity/neuroinflammation, and Parkinson's disease. Founded in 2019 and publicly listed via RTO in July 2021, the company's clinical work is primarily conducted in Brazil (UFRN, PI Prof. Dráulio de Araujo) and Argentina (Dr. Martin Bruno). Their BMND08 (sublingual 5-MeO-DMT for Alzheimer's depression) achieved a 100% remission rate in a Phase 2 RCT at subpsychedelic doses (February 2024) and is now advancing to FDA-directed Phase 3 via a proprietary nano-formulation platform with FDA Breakthrough Therapy Designation planned. BMND01 (inhaled DMT) is in Phase 2 for TRD with the unique advantage of a ~10-minute experience duration vs hours for psilocybin or LSD. Note: master list originally classified as private, but is publicly listed on NEO/CBOE.
View stakeholder →Universidade Estadual de Campinas (UNICAMP) / ICARO
Universidade Estadual de Campinas (UNICAMP) is home to ICARO, the Interdisciplinary Cooperation for Ayahuasca Research and Outreach, a research group based at the School of Medical Sciences focused on interdisciplinary ayahuasca research and outreach. ICARO has organized academic programming on ayahuasca and supports scientific and translational work on the plant medicine and related psychedelic topics.
View stakeholder →